Emerald Health Therapeutics Inc (OTCMKTS:EMHTF) shares closed last week by dipping under the key 50-day simple moving average to finish near a test of the $3/share level. The stock is trading down following a very predictable sell-the-news reaction to the Canadian legalization moment, which hit the tape last week. However, this pullback may be an interesting place to take a look at this rapidly growing name considering new catalysts coming into play.
As a case in point, the company recently announced that it has filed 17 provisional US patent applications covering Emerald’s unique Defined Dose cannabis dosage forms and formulations. According to the release, “Based on proprietary Emerald research, these patent applications are contributing to Emerald’s intellectual property portfolio and its intent to develop distinctive cannabis products for medical-use and improved adult-use. The products provide more precise and consistent delivery, dosage, and formulations. Defined Dose cannabis products will, when made available to the public, provide consumers with products currently not available.”
Emerald Health Therapeutics Inc (OTCMKTS:EMHTF) bills itself as a company that, together with its subsidiaries, produces and sells medical cannabis in Canada.
The next big cannabis story to hit North America is Phoenix Life Science International (PLSI), traded in the US, but with the largest global production based in the tropics and a license to distribute worldwide. Take a look at Phoenix Life Science International PLSI), Its currently trading under $18 dollars per share on the OTC markets. Learn More Now!
The company has a strong balance sheet, with cash levels far exceeding current liabilities ($72.7M against $26.3M). In addition, the company was formerly known as T-Bird Pharma Inc. and changed its name to Emerald Health Therapeutics, Inc. in June 2015. Emerald Health Therapeutics, Inc. is headquartered in Victoria, Canada.
Moreover, Emerald Health Therapeutics, Inc. is a Licensed Producer under Canada’s Access to Cannabis for Medical Purposes Regulations. Its 50%-owned Pure Sunfarms in BC is completing a sophisticated 1.1 million square feet greenhouse; its Agro-Biotech operation in Québec is completing a 75,000 square feet indoor facility.
Both facilities are in commercial production. It has also contracted for approximately 500 acres of hemp harvest in 2018 and 1000 acres in 2019 to 2022 with the goal of extracting low-cost cannabidiol (CBD). Emerald’s team is highly experienced in life sciences, product development, large-scale agri-business, and marketing, and is focused on developing proprietary, value-added cannabis products for medical and adult-use customers.
Emerald is part of the Emerald Health group, which is broadly focused on developing pharmaceutical, botanical, and nutraceutical products that may provide wellness and medical benefits by interacting with the human body’s endocannabinoid system.
Emerald Health Therapeutics Inc (OTCMKTS:EMHTF) pulled in sales of $284K in its last reported quarterly financials, representing top line growth of 15.7%.
Dropping Into the Basket
As we discussed earlier, EMHTF recently announced that it has filed 17 provisional US patent applications covering Emerald’s unique Defined Dose cannabis dosage forms and formulations. Even in light of this news, EMHTF has had a rough past week of trading action, with shares sinking something like -20% in that time.
That said, chart support is nearby and we may be in the process of constructing a nice setup for some movement back the other way.
“We expect significant potential cannabis market growth by offering adult users and medical consumers consistent product characteristics, dosing regimens, and alternative methods of consumption, with safety enhanced through GMP-compliant production and enhanced product utility achieved through knowledge of science. Emerald’s filing of these patent applications is an important step,” said Chris Wagner, CEO of Emerald.
“Our expanding research and development effort is focused on internal facilities and staff as well as forming key relationships with other cannabis research experts, such as our recently announced agreement with VivaCell Biotechologies Espana.”
As noted above, the stock has been weakening in recent days. But there are plenty of reasons to see any downside here as an opportunity.
Pushing the barriers for global distribution, Phoenix Life Science International (PLSI) is the next cannabis play. Just think Canopy x 100, that is how big their plantation in the tropics will be. No lights, no green houses, just maximum growth + minimal cost = home run. Learn More Now!
The Green Organic Dutchman Holdings Ltd (OTCMKTS:TGODF) Roller Coaster Ride Continues
Green Organic Dutchman Holdings Ltd (OTCMKTS:TGODF) just announced its financial and operational results for the third quarter of fiscal 2018,...
Puration Inc (OTCMKTS:PURA) Catches a Fresh Bid on New Numbers
Puration Inc (OTCMKTS:PURA) just announced its third quarter financial report for the period ending September 30, 2018. According to the...
Why Expectations May be Dropping for Tilray Inc (NASDAQ:TLRY)
Tilray Inc (NASDAQ:TLRY) just reported financial results for the third quarter and nine months ended September 30, 2018. The company...
Why OrganiGram Holdings Inc (OTCMKTS:OGRMF) Gets More and More Interesting on the Pullback
OrganiGram Holdings Inc (OTCMKTS:OGRMF) recently announced that the company has signed a supply agreement with the Province of British Columbia....
Namaste Technologies Inc (OTCMKTS:NXTTF) Looks for Some More Magic
Namaste Technologies Inc (OTCMKTS:NXTTF) recently announced that the company has acquired over 28,000 registered users through NamasteMD Inc, and that...
A Sober Look at Green Organic Dutchman Holdings Ltd (OTCMKTS:TGODF)
Green Organic Dutchman Holdings Ltd (OTCMKTS:TGODF) has presented itself as somewhat of a mystery item in the space. The company...
Marimed Inc (OTCMKTS:MRMD) Taps Wall Street Talent for M&A Strategy
Marimed Inc (OTCMKTS:MRMD) recently announced it has named Charles Finnie as its Chief Strategy Officer, effective immediately. Finnie, who most...
Why the Latest Dip in New Age Beverages Corp (NASDAQ:NBEV) May Be a Major Gift
New Age Beverages Corp (NASDAQ:NBEV) is starting to drift down into very interesting territory from both a technical and a...
Pyxus International Inc (NYSE:PYX) Could be an Opportunity in the Making
Pyxus International Inc (NYSE:PYX) shares were hammered to close out the week after announcing relatively dreadful fiscal Q2 results, which...
Aurora Cannabis Inc (NYSE:ACB) Shares Rebound as Company Turns Focus to South American Market
Aurora Cannabis Inc (NYSE:ACB) just acquired ICC Labs, or so appears to be the case. As a point in fact,...